See more : Signaux Girod S.A. (ALGIR.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Dakshidin Corporation, Inc. (DKSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dakshidin Corporation, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- DTXS Silk Road Investment Holdings Company Limited (0620.HK) Income Statement Analysis – Financial Results
- Outlook Therapeutics, Inc. (OTLK) Income Statement Analysis – Financial Results
- Fnac Darty SA (FNAC.PA) Income Statement Analysis – Financial Results
- MIC Electronics Limited (MICEL.NS) Income Statement Analysis – Financial Results
- Medinova Diagnostic Services Limited (MEDINOV.BO) Income Statement Analysis – Financial Results
Dakshidin Corporation, Inc. (DKSC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Dakshidin Corporation, Inc.
Dakshidin Corporation, Inc., through its subsidiaries, operates as a CBD/cannabis-based medical product company. It cultivates cannabis; and operates an online sales portal for CBD products. The company also manages distribution channel programs in the retail distribution, reselling, and direct sales market segments. Dakshidin Corporation, Inc. was formerly known as Avrada, Inc. and changed its name to Dakshidin Corporation, Inc. in February 2007. The company is based in Miami, Florida with additional offices in Las Vegas, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.48K | 208.25K | 19.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 165.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 2.48K | 42.40K | 19.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 20.36% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 6.55K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.72K | 167.09K | 219.32K | 50.28K | 195.91K | 13.63K | 2.30K | 2.20K | 147.40K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.72K | 167.09K | 219.32K | 50.28K | 202.46K | 13.63K | 2.30K | 2.20K | 147.40K |
| Cost & Expenses | 17.72K | 167.09K | 219.32K | 216.13K | 202.46K | 13.63K | 2.30K | 2.20K | 147.40K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.72K | -167.09K | -216.84K | -7.88K | -183.40K | -13.63K | -2.30K | -2.20K | -147.40K |
| EBITDA Ratio | 0.00% | 0.00% | -8,743.55% | -3.78% | -961.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.72K | -167.09K | -216.84K | -7.88K | -183.40K | -13.63K | -2.30K | -2.20K | -147.40K |
| Operating Income Ratio | 0.00% | 0.00% | -8,743.55% | -3.78% | -961.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 4.00 | -4.00 | 5.00 | 0.00 |
| Income Before Tax | -17.72K | -167.09K | -216.84K | -7.88K | -183.40K | -13.63K | -2.30K | -2.20K | -147.40K |
| Income Before Tax Ratio | 0.00% | 0.00% | -8,743.43% | -3.78% | -961.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -17.72K | -167.09K | -216.84K | -7.88K | -183.40K | -13.63K | -2.30K | -2.20K | -147.40K |
| Net Income Ratio | 0.00% | 0.00% | -8,743.43% | -3.78% | -961.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 3.34B | 2.58B | 2.56B | 2.50B | 2.50B | 1.97B | 1.97B | 1.97B | 730.36M |
| Weighted Avg Shares Out (Dil) | 3.34B | 2.58B | 2.56B | 2.50B | 2.50B | 1.97B | 1.97B | 1.97B | 730.36M |
Dakshidin Corporation Marks Strategic Milestone with Stenergy LLC's IP Acquisition and COO Appointment
Whitechapel Announces Its Webinar Series - “Webinars for Living”
Dakshidin Corporation (OTC: DKSC) Relaunches Updated Whitechapelholdingsusa.com & Laughingfrogs.com Websites
Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
Dakshidin Corporation Signs Business Development Deal With Cicero Media Group
Source: https://incomestatements.info
Category: Stock Reports